DataMeds AI, Inc. (MEDS) entered into a non-binding Second Amended and Restated Letter of Intent dated October 19, 2026, replacing its prior term sheet and letter of intent. The proposal would add QLPM intellectual property from EOS and Scilex, expand the exclusive Datavault AI Health license subject to carve-outs, acquire a controlling interest in Health Lives Here from HBA and THI, and license REBOOT intellectual property and services. Consideration would include common stock, with Fortitude receiving shares under a separate agreement. Target post-closing ownership is approximately 89.5% for recipients collectively and 10.5% for existing public holders, on a fully diluted basis.
Closing is expected in the fourth quarter of 2026, subject to definitive agreements, due diligence, required approvals and a liability-reduction framework; the Definitive Agreements are to set a closing threshold of not more than $2,000,000 in permitted indebtedness and liabilities. REBOOT may close separately or not at all and is not a condition to closing with other parties. Proposed royalties are 6% of adjusted net revenue attributable to REBOOT IP and 5% of gross revenue from each of the EOS and Scilex QLPM portfolios. A resale registration for specified Acquisition Stock is contemplated within 45 days following closing, with commercially reasonable efforts toward effectiveness within 90 days; a six-month lock-up is also contemplated.
DataMeds AI, Inc. (MEDS) regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving written notice from Nasdaq staff on October 19, 2026. The rule requires at least $2,500,000 in stockholders’ equity; DataMeds said an October 13 company filing confirmed equity exceeded that threshold, and an October 16 filing provided details of the material events that resulted in exceeding it.
Earlier, Nasdaq notified the company on April 13, 2026 that its annual report for the fiscal year ended December 31, 2025 reported stockholders’ equity of -$12,447,801, below the minimum, and that it did not meet the rule’s alternative market-value or net-income standards. Nasdaq notified the company on June 9, 2026 that it had regained bid-price compliance and granted additional time to meet the equity requirement. DataMeds said it may be subject to delisting if its next periodic report does not evidence compliance.
DataMeds AI, Inc. (MEDS) entered an exclusive U.S. license to REBOOT Health AI, Inc.’s licensed patents and to use its platform, limited to DataMeds’ direct-to-consumer (B2C) GLP-1 weight-management business. The license excludes direct sales to healthcare providers for healthcare business use, subject to limited exceptions. DataMeds issued 666,667 common shares valued at $2,000,000 and agreed to pay $50,000 within two business days of execution toward reconfiguration, with an estimated minimum aggregate cost of $100,000. If the shares’ market value is below $2,000,000 180 days after the Effective Date, DataMeds must issue additional shares using the 10-day volume-weighted average price as of that date. The parties also agreed to revenue sharing, under which REBOOT will receive a portion of Adjusted Gross Revenue after certain costs.
From July 2026 to October 2026, DataMeds converted approximately $1.5 million of vendor payables into common stock; a settlement extinguished approximately $18.7 million of debt. DataMeds believes its stockholders’ equity exceeds Nasdaq’s $2,500,000 continued-listing threshold, but awaits formal confirmation. Nasdaq will continue monitoring, and if the next periodic report does not evidence compliance, DataMeds may be subject to delisting proceedings.
DataMeds AI, Inc. entered a settlement agreement and release and paid $450,000: $350,000 was aggregate consideration for repurchasing and extinguishing 364,099 common shares, and $100,000 was for the compromise and settlement of the MIPA and other released claims. The agreement extinguished approximately $19 million in liability shown on the company’s consolidated balance sheet.
DataMeds stated that its stockholders’ equity was greater than $2,500,000 as of October 13, 2026, and that the transactions increased equity. Separately, on October 13, 2026, it licensed a care management platform from REBOOT Health AI, Inc. for integration into its business model and issued REBOOT 666,667 common shares.
DataMeds AI, Inc. (MEDS) says holders of 1,604,920 shares, or 50.2% of common stock, approved corporate actions by written consent dated August 25, 2026. The approval becomes effective 20 calendar days after the information statement is first sent. The actions include an amendment authorizing up to 1,000,000 preferred shares; after effectiveness, DataMeds expects to file the amendment and designate 25,000 shares as Series A preferred stock, issuable upon conversion of the May 2026 notes.
The notes have $21,132,812.50 aggregate principal, mature 12 months after issuance unless earlier converted or repaid, and convert at a market-linked price. At an illustrative $0.50 conversion price, conversion of all notes would issue approximately 42,264,000 common shares; $0.50 is not a floor, and lower prices could result in more shares. Series A shares, if issued, accrue dividends at 10% of stated value over each 12-month period beginning six months after issuance, added monthly to stated value. Stockholders also approved issuance to Silverback Capital Corporation under a January 28, 2026 settlement agreement beyond Nasdaq's 20% threshold, elected Prashant Patel, Suren Ajjarapu, Donald Fell, Gary Herman and Marlene Velez to serve until the 2027 annual meeting and their successors, and ratified Suri & Co. as auditor for 2026.
DataMeds AI, Inc. (MEDS) registers up to 34,462,057 shares of common stock for resale by selling stockholders. The amount includes 1,282,143 previously issued shares; 21,300,295 shares issuable upon conversion of the May 2026 Notes or resulting Series A Preferred Stock, calculated using an assumed $1.00 conversion price; 8,298,225 PIPE Warrant shares; and 3,581,394 placement-agent warrant shares. DataMeds is not selling shares: selling stockholders receive resale proceeds, while DataMeds may receive proceeds if warrants are exercised for cash, for working capital and general corporate purposes.
The May 2026 Notes’ Mandatory Conversion Date is the latest of registration statement effectiveness, stockholder approval of the blank-check preferred amendment, effectiveness of that amendment, and filing of the Series A certificate of designation; conversion is subject to a 9.99% beneficial ownership cap. DataMeds reported 4,515,862 common shares outstanding as of September 28, 2026. At the $3.81 closing price on that date, conversion of all notes would issue approximately 5,546,670 shares, which the prospectus estimates would represent approximately 55.1% dilution to existing stockholders.
DataMeds AI, Inc. (MEDS) entered into a settlement agreement and release with Brian Norton and related parties concerning disputes over a Membership Interest Purchase Agreement and related company obligations. Under the agreement, DataMeds paid $450,000, including $350,000 attributed to the repurchase and extinguishment of 364,099 shares of common stock and $100,000 allocated to the compromise and settlement of the MIPA and other released claims.
DataMeds anticipates extinguishing approximately $19 million of liability that appears on its consolidated balance sheet as a result of this agreement. The parties agreed to dismiss the related Florida and Delaware litigations with prejudice and to exchange mutual releases of claims, resolving these disputes on a final basis.
DataMeds AI, Inc. (MEDS) completed the acquisition of Helomics Corporation from Axe Compute Inc. on September 11, 2026, purchasing all Helomics shares for 636,328 shares of DataMeds common stock (about 19.99% of pre-deal shares) and a $1,363,672 convertible promissory note.
The note bears 7% simple annual interest and matures on September 11, 2029, with voluntary conversion at a $1.00 per share price, subject to stockholder approval and full-ratchet anti-dilution adjustments if future equity is issued below the then-current conversion price. DataMeds agreed to seek stockholder approval for conversion within 75 days of closing. Helomics, a CLIA/CAP-certified AI cancer diagnostics lab and precision oncology CRO business, becomes a wholly owned subsidiary, and DataMeds also receives the Helomics lab, related oncology CRO operations, and $1.5 million in cash, with no third-party debt or unpaid accounts payable beyond normal operating expenses, supporting expansion into oncology services.
DataMeds AI, Inc. (MEDS) reports that holders of 50.2% of its common stock, representing a majority of the 3,197,633 shares outstanding as of August 18, 2026, have approved by written consent several corporate actions without a meeting or proxy solicitation.
The approvals include a “blank check” preferred stock amendment authorizing up to 1,000,000 preferred shares and the prompt designation of 25,000 shares as Series A Convertible Preferred Stock tied to the May 2026 financing. That financing involved $21.13 million principal of 0% May 2026 Notes and warrants, potentially convertible into common stock at variable prices with floors as low as $1.00 per share.
DataMeds provides dilution tables showing that, depending on conversion prices, combined conversions of the May 2026 Notes or Series A Preferred Stock and exercises of related PIPE and placement agent warrants could result in dilution of existing common stockholders up to the 90%+ range. The Series A Preferred Stock carries a 10% annual dividend added to stated value, voting rights, and priority in liquidation, and the company notes potential anti-takeover effects from the blank check preferred authorization. Stockholders also approved the reelection of five directors to serve until the 2027 annual meeting, Nasdaq Listing Rule 5635(d) approval for prior and potential issuances to Silverback Capital Corporation, and ratification of Suri & Co. as independent auditor for 2026.
DataMeds AI, Inc. reported second quarter 2026 net revenues of $1.78 million, down sharply from $7.79 million a year earlier, but up 14% sequentially from the first quarter, exceeding internal projections. Gross profit was $0.18 million, and the company recorded an operating loss of $7.35 million.
After $11.02 million in net other expense, including an $8.88 million loss on extinguishment of debt, net loss for the quarter was $18.36 million, or $7.13 per share. Total assets were $32.76 million against liabilities of $52.26 million, resulting in a stockholders’ deficit of $19.50 million.
The company highlighted a pending Datavault Transaction, a planned September 2026 launch of the Health Lives Here app with NFL Alumni Health targeting GLP‑1 users, a $6.5 million capital raise, restructuring of $14.5 million in debt toward a preferred equity swap, a 1-for-50 reverse stock split, and new lock-up agreements covering about 49% of outstanding shares.